Lund, Sweden

Carl Sandén

This inventor holds 1 USPTO granted patent. Top assignee: Lead Biologics International Ab. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Carl Sandén. Retrieved from https://idiyas.com/inventor/carl-sanden

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Carl Sandén and His Work in Hematologic Cancer Research.

Introduction

Carl Sandén is an inventor associated with Lund, Sweden, and Lead Biologics International AB. His patent work focuses on SLAMF6-targeting agents and their potential applications in neoplastic hematologic disorders. The supplied information lists 1 patent.

Latest Patents

Sandén’s listed patent, “Agents and uses thereof,” describes agents that bind specifically to Signaling Lymphocytic Activating Molecule Family Member 6 (SLAMF6). The invention proposes using these agents to induce cell death or inhibit the growth and proliferation of pathological stem cells and progenitor cells associated with neoplastic hematologic disorders, when those cells express SLAMF6. It also addresses modulating interactions between these cells and immune cells that may express SLAMF6.

The patent further describes using SLAMF6-binding agents to detect pathological stem cells, progenitor cells, and immune cells associated with these disorders. It also covers related pharmacological compositions and methods of use.

Career Highlights

Sandén’s listed patent reflects work at the intersection of targeted biologics, cancer research, and immune-cell interactions. The invention’s proposed uses include both detecting relevant cells and targeting them for therapeutic purposes.

Collaborations

The supplied information identifies Thoas Fioretos and Niklas Landberg as Sandén’s coworkers. It also associates Sandén with Lead Biologics International AB.

Conclusion

Carl Sandén’s listed invention centers on SLAMF6-binding agents with potential diagnostic and therapeutic applications in neoplastic hematologic disorders.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…